Carole M Ehleben

Learn More
BACKGROUND & AIMS The efficacy and safety of interferon-free regimens for the treatment of chronic hepatitis C virus (HCV) infections require further evaluation and comparison with those of interferon-containing regimens. We compared a regimen of peginterferon, ribavirin, and sofosbuvir with a regimen of simeprevir and sofosbuvir in patients with HCV(More)
drugs, the absence of interaction between clopidogrel and H2 antihistamines (and even antacids) mentioned by the FDA ( 4 ) calls for a critical appraisal of their place in therapy, which must crucially be addressed, especially in hemorrhagic high-risk patients. (v) Finally, from a practical point of view, both clopidogrel and omeprazole are very useful(More)
To determine the impact of pre-operative and intra-operative ilioinguinal and iliohypogastric nerve block on post-operative analgesic utilization and length of stay (LOS). We conducted a prospective randomized double-blind placebo controlled trial to assess effectiveness of ilioinguinal-iliohypogastric nerve block (IINB) on post-operative morphine(More)
UNLABELLED The new standard of care for treatment-naïve patients with hepatitis C virus (HCV) genotype 1 includes triple therapy with peginterferon, ribavirin, and a protease inhibitor. However, patients who achieve a rapid virologic response after 4 weeks of peginterferon and ribavirin therapy are likely to achieve a sustained virologic response (SVR), and(More)
We read the interesting article by Vilana et al., who reported that intrahepatic cholangiocarcinoma (ICC) arising in the cirrhotic liver may display on contrast-enhanced ultrasound (CEUS) a vascular pattern indistinguishable from that of hepatocellular carcinoma (HCC). Such a typical dynamic imaging pattern after intravenous contrast administration (i.e.,(More)
We read with great interest the article entitled ‘‘Ethnic Differences in Viral Dominance Patterns in Patients with Hepatitis B Virus and Hepatitis C Virus Dual Infection,’’ recently published by Nguyen et al. in this journal. The study was designed to evaluate and compare the demographic, clinical, and viral characteristics of multiethnic patients infected(More)
genotype was significantly associated with treatment response in each arm of the trial (P5 0.04, Fisher’s exact test; Fig. 1). It appears, therefore, that a very high proportion of patients with a favorable host genotype who meet the selection criteria for this trial will achieve SVR with 24 weeks of peg-interferon-a/ribavirin alone. Otherwise similar(More)
  • 1